These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 17435554)

  • 1. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram.
    Park J; Fey JV; Naik AM; Borgen PI; Van Zee KJ; Cody HS
    Ann Surg; 2007 Mar; 245(3):462-8. PubMed ID: 17435554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram.
    Specht MC; Kattan MW; Gonen M; Fey J; Van Zee KJ
    Ann Surg Oncol; 2005 Aug; 12(8):654-9. PubMed ID: 16021535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND.
    Goyal A; Newcombe RG; Chhabra A; Mansel RE
    Ann Surg Oncol; 2008 Jan; 15(1):262-7. PubMed ID: 17879117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of completion axillary lymph node dissection in patients with immunohistochemical metastases to the sentinel lymph node in breast cancer.
    Pugliese MS; Karam AK; Hsu M; Stempel MM; Patil SM; Ho AY; Traina TA; Van Zee KJ; Cody HS; Morrow M; Gemignani ML
    Ann Surg Oncol; 2010 Apr; 17(4):1063-8. PubMed ID: 20033325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy.
    Alran S; De Rycke Y; Fourchotte V; Charitansky H; Laki F; Falcou MC; Benamor M; Freneaux P; Salmon RJ; ; Sigal-Zafrani B
    Ann Surg Oncol; 2007 Aug; 14(8):2195-201. PubMed ID: 17294071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative validation of online nomograms for predicting nonsentinel lymph node status in sentinel lymph node-positive breast cancer.
    Hessman CJ; Naik AM; Kearney NM; Jensen AJ; Diggs BS; Troxell ML; Vetto JT
    Arch Surg; 2011 Sep; 146(9):1035-40. PubMed ID: 21931000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High intersystem variability for the prediction of additional axillary non-sentinel lymph node involvement in individual patients with sentinel node-positive breast cancer.
    van den Hoven I; Kuijt GP; Voogd AC; Roumen RM
    Ann Surg Oncol; 2012 Jun; 19(6):1841-9. PubMed ID: 22207045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
    Fan YG; Tan YY; Wu CT; Treseler P; Lu Y; Chan CW; Hwang S; Ewing C; Esserman L; Morita E; Leong SP
    Ann Surg Oncol; 2005 Sep; 12(9):705-11. PubMed ID: 16079953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sentinel node mapping for breast cancer: the operative experience of a breast surgeon in a rural community.
    Davit FE; Gatmaitan P; Garguilo G
    Am Surg; 2008 May; 74(5):423-7. PubMed ID: 18481500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram.
    Cripe MH; Beran LC; Liang WC; Sickle-Santanello BJ
    Am J Surg; 2006 Oct; 192(4):484-7. PubMed ID: 16978955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients.
    Langer I; Guller U; Berclaz G; Koechli OR; Schaer G; Fehr MK; Hess T; Oertli D; Bronz L; Schnarwyler B; Wight E; Uehlinger U; Infanger E; Burger D; Zuber M
    Ann Surg; 2007 Mar; 245(3):452-61. PubMed ID: 17435553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node.
    Rivers AK; Griffith KA; Hunt KK; Degnim AC; Sabel MS; Diehl KM; Cimmino VM; Chang AE; Lucas PC; Newman LA
    Ann Surg Oncol; 2006 Jan; 13(1):36-44. PubMed ID: 16378156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a nomogram to predict the risk of nonsentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy: validation of the MSKCC breast nomogram.
    van la Parra RF; Ernst MF; Bevilacqua JL; Mol SJ; Van Zee KJ; Broekman JM; Bosscha K
    Ann Surg Oncol; 2009 May; 16(5):1128-35. PubMed ID: 19252954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
    Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.
    Naik AM; Fey J; Gemignani M; Heerdt A; Montgomery L; Petrek J; Port E; Sacchini V; Sclafani L; VanZee K; Wagman R; Borgen PI; Cody HS
    Ann Surg; 2004 Sep; 240(3):462-8; discussion 468-71. PubMed ID: 15319717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
    Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK
    Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solitary positive sentinel lymph node accompanied by negative sentinel lymph node(s) is predictive of a negative completion axillary lymph node dissection.
    Alkhatib W; Connor C; Fang F
    Am J Surg; 2007 Dec; 194(6):856-8; discussion 858-9. PubMed ID: 18005784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
    Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence.
    Port ER; Garcia-Etienne CA; Park J; Fey J; Borgen PI; Cody HS
    Ann Surg Oncol; 2007 Aug; 14(8):2209-14. PubMed ID: 17268882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.